Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?
Macrolide monotherapy is currently recommended as first-line treatment of mild-to-moderate community-acquired pneumonia (CAP) in penicillin-intolerant/allergic individuals in the UK. However, resistance rates among the commonest cause, Streptococcus pneumoniae, now exceed 10% in the UK and a review of alternative agents is therefore timely. This review considers the relative merits of two agents, doxycycline and moxifloxacin, which are candidates to replace macrolides for second-line therapy of non-severe CAP.
Ludlam
H A
HA
Clinical Microbiology & Public Health Laboratory, Box 236, Addenbrooke's Hospital, Cambridge University NHS Foundation Trust, Hills Road, Cambridge, UK.
Enoch
D A
DA
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D004318:Doxycycline / Q000627:therapeutic use*; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D011804:Quinolines / Q000627:therapeutic use*; D016896:Treatment Outcome; D006113:United Kingdom
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D004318:Doxycycline; D000077266:Moxifloxacin